Image provided by Unsplash
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a U.S.-based biotech company with the goal of researching and developing novel brain disorder treatments. Its subsidiary Pasithea Clinics offers ketamine-infusion therapy geared toward improving the symptoms of certain mental health disorders.
Pasithea Clinics has launched in major U.S. and U.K. cities, including London, New York City, Los Angeles, San Diego, and San Francisco, and reports that it is quickly gearing up to add new locations nationwide and internationally.
Mobile clinics may be becoming an increasingly recognized solution for making healthcare more affordable, accessible, and improving patient outcomes. Pasithea states that it is committed to this goal and dedicated to making treatments more accessible to all patients — especially those suffering from brain disorders.
Intravenous (IV) ketamine therapy is designed to treat the symptoms of various mental health disorders — especially treatment-resistant depression and post-traumatic stress disorder. Pasithea Clinics are meant to enable patients to receive ketamine therapy in the …
Original Source: benzinga.com
